Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...
Though the renal protection provided by antihypertensive doses of ACE inhibitors and ARBs has been extensively studied, the dose response of these agents may be different for renal protection.
Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
9 European Union (EU) Innovative Medicines Initiative (IMI) Program Understanding Severe Asthma, Consortium Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) ...
The official React Native and Expo components for Stream Chat, a service for building chat applications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results